丹参酮ⅡA磺酸钠治疗肺心病合并尘肺临床观察

Observation of clinical efficacy and safety of sodium Tanshinone ⅡA sulfonate in the treatment of cor pulmonale complicated with pneumoconiosis

目的肺心病属于支气管-肺组织或肺动脉血管病变引发的肺动脉高压心脏疾病,易产生并发症,预后不理想。本研究探讨肺心病合并尘肺患者接受丹参酮ⅡA磺酸钠进行治疗的具体方法、治疗效果以及安全性,为临床治疗提供可靠依据。方法选取2016-01-15-2017-01-15枣庄矿业集团中心医院收治的肺心病合并尘肺患者100例,根据治疗方法的不同分为研究组和对照组各50例。两组均实施常规治疗,研究组在此基础上加用丹参酮ⅡA磺酸钠,比较两组血流动力学指标,临床疗效及不良反应。结果治疗后,研究组高切变率全血黏度为(7.00±1.00)mPa·s,低于对照组(9.10±1.20)mPa·s,t=9.506,P<0.001;研究组低切变率全血黏度为(4.90±0.80)mPa·s,低于对照组(5.40±0.90)mPa·s,t=2.936,P=0.004;研究组血浆比黏度为(1.57±0.08)mPa·s,低于对照组(1.77±0.16)mPa·s,t=7.906,P<0.001;研究组红细胞聚集指数为(1.39±0.07)mPa·s,低于对照组(1.46±0.08)mPa·s,t=4.656,P<0.001,研究组血细胞比容为(41.00±4.30)mPa·s,低于对照组(47.60±5.20)mPa·s,t=6.916,P<0.001,研究组血小板聚集率为(0.48±0.06)mPa·s,低于对照组(0.62±0.11)mPa·s,t=7.901,P<0.001。研究组治疗总有效率为90.0%,高于对照组68.0%,χ2=10.425,P<0.05。研究组不良反应发生率为6.0%,低于对照组12.0%,但差异无统计学意义,χ2=1.778,P=0.182。结论针对肺心病合并尘肺患者接受丹参酮ⅡA磺酸钠进行治疗效果明显,能够改善患者血流动力学,治疗方法安全可靠。

OBJECTIVE Pulmonary heart disease is a pulmonary hypertension heart disease caused by bronchial lung tissue or pulmonary artery disease.It is easy to cause complications and the prognosis is not ideal.The study explores the specific methods,therapeutic effects and safety of sodium Tanshinone ⅡA sulfonate for patients with cor pulmonale and pneumoconiosis,and to provide a reliable basis for the clinical treatment of this disease.METHODS A total of 100 patients with cor pulmonale and pneumoconiosis treated in Central Hospital of Zaozhuang Mining Group from January 15,2016 to January 15,2017 were selected and divided into the study group and the control group according to different treatment methods,with 50 cases in each group.The two groups were treated with routine therapy.On the basis,the sodium TanshinoneⅡA sulfonate was added in the study group,the hemodynamic indexes,clinical effects and adverse reactions between the two groups were compared.RESULTS After treatment,the total blood viscosity of the study group was（7.00±1.00）mPa·s,lower than that of the control group（9.10±1.20）mPa·s,t=9.506,P〈0.001.The low shear rate of the study group was（4.90±0.80）mPa·s,lower than the control group（5.40±0.90）mPa·s,t=2.936,P=0.004.The plasma specific viscosity of the study group was（1.57±0.08）mPa·s,lower than the control group（1.77±0.16）mPa·s,t=7.906,P〈0.001.The erythrocyte aggregation index of the study group was（1.39±0.07）mPa·s,which was lower than that of the control group（1.46±0.08）mPa·s,t=4.656,P〈0.001.The blood cell specific volume of the study group was（41.00±4.30）mPa·s,t=6.916,P〈0.001.The platelet aggregation rate of the study group was（0.48±0.06）mPa·s,lower than that of the control group（0.62±0.11）mPa·s,t=7.901,P〈0.001.The effective rate of the study group（90.0%）was significantly higher than that of the control group（68.0%）,χ^2=10.425,P〈0.05.The adverse reaction rate（6.0%）in the study group was lower than that in the control group（12.0%）,but the difference was not statistically significant,χ^2=1.778,P=0.182.CONCLUSION The sodium TanshinoneⅡA sulfonate is obviously effective in treatment of patients with cor pulmonale and pneumoconiosis,and the treatment method is safe and reliable.